Navigation Links
MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
Date:6/9/2008

ORCHARD PARK, N.Y., June 9 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced it has received approval from the U.S. Food and Drug Administration Center for Veterinary Medicine to market Petrem(TM) (Sevoflurane) inhalation anesthetic. This week they have initiated their US product launch to the veterinary market.

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB-A, filed with the Securities and Exchange Commission on April 21, 2008.. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

CONTACT:

Charles R. Trego, Jr.

Executive Vice President and CFO

E-mail: ctrego@minrad.com


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MINRAD International, Inc. Announces 2007 Financial Results
2. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
3. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
4. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
5. Jury Rules in Favor of Glycoproducts International, Inc.
6. Lockheed Martin Completes Acquisition of Eagle Group International, LLC
7. Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington
8. China Yingxia International, Inc. Reports First Quarter 2008 Results
9. Natural Alternatives International, Inc. Announces Third Quarter Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. CalbaTech, Inc. Officially Changes Name to LifeStem International, Inc.; Lists New Symbol (LSTM) and Launches New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: